Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Atorvastatin side effects heart palpitations?
Does lipitor's use influence blood pressure medication type?
Motegrity ingredients?
When will latisse patent expire?
Combivent inhaler hfc 152a patents?

Owners of mounjaro?

See the DrugPatentWatch profile for mounjaro

Eli Lilly and Company holds the ownership of Mounjaro [1]. Mounjaro is a medication approved for the treatment of type 2 diabetes [2].

What is Mounjaro used for?


Mounjaro (tirzepatide) is a medication indicated to improve glycemic control in adults with type 2 diabetes mellitus [2]. It is also being investigated for other indications, including obesity [3].

How does Mounjaro work?


Mounjaro is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By activating both receptors, tirzepatide helps to lower blood glucose levels and promote weight loss [4].

When does Mounjaro's patent expire?


Information on Mounjaro's patent expiry dates can be found on DrugPatentWatch.com [5]. Patent exclusivity is crucial for pharmaceutical companies as it determines the period during which generic versions of the drug cannot be marketed.

Who are Mounjaro's competitors?


Mounjaro competes in the diabetes and weight loss market with other GLP-1 receptor agonists and dual agonists. Key competitors include semaglutide (Ozempic, Wegovy) manufactured by Novo Nordisk, and other GLP-1 receptor agonists like liraglutide (Victoza, Saxenda) [6].

What clinical data supports Mounjaro's use?


Clinical trials have demonstrated Mounjaro's efficacy in reducing A1C levels and body weight in individuals with type 2 diabetes [2, 4]. These studies have provided the basis for its regulatory approvals [2].

What are the potential side effects of Mounjaro?


Common side effects of Mounjaro include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. More serious, though less common, side effects can occur [2].

Can Mounjaro be used for weight loss?


While Mounjaro is approved for type 2 diabetes, tirzepatide has shown significant weight loss effects. Eli Lilly has sought and obtained approval for tirzepatide for chronic weight management in individuals with obesity or overweight with at least one weight-related condition [3].

What is the price of Mounjaro?


The price of Mounjaro can vary based on insurance coverage, pharmacy, and location. Information on drug pricing is typically available through pharmacies and insurance providers [7].

What are the regulatory approvals for Mounjaro?


Mounjaro has received approval from regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for its indicated uses [2].

---
Sources:

[1] Eli Lilly and Company. (n.d.). Eli Lilly and Company. Retrieved from https://www.lilly.com/
[2] Mounjaro Prescribing Information. (n.d.). U.S. Food and Drug Administration.
[3] Eli Lilly and Company. (2023, November 8). Eli Lilly announces U.S. FDA approval of Zepbound™ (tirzepatide) for chronic weight management [Press release].
[4] Frias JP, Davies MJ, Stone L, et al. Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519
[5] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[6] Novo Nordisk. (n.d.). Novo Nordisk. Retrieved from https://www.novonordisk.com/
[7] GoodRx. (n.d.). Mounjaro Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/mounjaro



Other Questions About Mounjaro :

How long does it take for mounjaro to start working? Mounjaro ndc list? What is the generic brand for mounjaro? Eli lilly mounjaro patent expiry us? What ingredients are in mounjaro? When will generic mounjaro be available uk? How quickly does Mounjaro work?

AI-Drug Label Prescribing Information Alignment Report

82
82%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The AI response largely aligns with the FDA label for MOUNJARO. Indication, mechanism, pharmacodynamics, and key efficacy statements are supported by label sections. Several statements (notably about obesity indications, broad regulatory approvals, common adverse effects, and off-label use) are not present in the label, resulting in partial alignment.

Category Scores

Indication
100
Excellent
AdverseReactions
60
Partial

Accurate Statements

Mounjaro is indicated to improve glycemic control in adults with type 2 diabetes mellitus.
Indication (1)
Mounjaro is approved for the treatment of type 2 diabetes.
Indication (1)
Mounjaro (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
12.1
By activating both receptors, tirzepatide helps to lower blood glucose levels.
12.2
By activating both receptors, tirzepatide promotes weight loss.
12.2
Clinical trials have demonstrated Mounjaro's efficacy in reducing A1C levels in individuals with type 2 diabetes.
14.1
Clinical trials have demonstrated Mounjaro's efficacy in reducing body weight in individuals with type 2 diabetes.
12.2, 14.1
More serious, though less common, adverse effects can occur.
6

Unsupported Statements

Mounjaro is being investigated for other indications, including obesity.
Absent_from_label
These studies have provided the basis for its regulatory approvals.
Absent_from_label
Common side effects of Mounjaro include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation.
Absent_from_label
Mounjaro has received approval from regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for its indicated uses.
Absent_from_label
Eli Lilly has sought and obtained approval for tirzepatide for chronic weight management in individuals with obesity or overweight with at least one weight-related condition.
Absent_from_label

Contradictions

Important Omissions

Pediatric indication (patients 10 years and older) is not addressed in the claims, though the label states indication in adults and pediatric patients 10 years and older.
Importance: High
Boxed warnings (e.g., risk of thyroid C-cell tumors) and major safety warnings are not discussed.
Importance: High

Safety Assessment

Potential Patient Risk: Low
Most statements pertain to mechanism and efficacy with limited safety detail; some safety-related statements are marked as absent_from_label, indicating gaps relative to the label.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Missing pediatric indication details, boxed warnings, and common adverse event information.

Suggested Improvement
Include pediatric use details, boxed warnings (e.g., thyroid C-cell tumor risk), and common adverse events to improve alignment with the labeling.

Drug Brand Mention Assessment

Branding Score
65
Visibility
80
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

Mounjaro is a dual GIP and GLP-1 receptor agonist.

Core Claims
  • Mounjaro (tirzepatide) is a medication indicated to improve glycemic control in adults with type 2 diabetes mellitus.
  • Mounjaro is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
  • Mounjaro competes in the diabetes and weight loss market with other GLP-1 receptor agonists and dual agonists.
  • Information on Mounjaro's patent expiry dates can be found on DrugPatentWatch.com.
  • Mounjaro has received approval from regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for its indicated uses.
Differentiators
  • Dual GIP and GLP-1 receptor agonist.
  • Indicated to improve glycemic control in adults with type 2 diabetes mellitus.
  • tirzepatide has shown significant weight loss effects.
  • has sought and obtained approval for tirzepatide for chronic weight management in individuals with obesity or overweight with at least one weight-related condition.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Novo Nordisk 44%
50 #2 No